Medpace Holdings, Inc. to Report First Quarter 2023 Financial Results on April 24, 2023

Rhea-AI Summary

Medpace Holdings (Nasdaq: MEDP) will report its Q1 2023 financial results on April 24, 2023, after market close. A conference call is scheduled for April 25, 2023, at 9:00 a.m. ET to discuss these results. Interested participants can register in advance through a provided link and are encouraged to join 10 minutes early. The call will also be accessible via webcast on Medpace's investor relations website, where a replay will be available afterwards. Additionally, a supplemental slide presentation will be posted on the site prior to the call.

Positive

• Upcoming Q1 2023 financial results announcement may drive investor interest.
• Scheduled conference call provides a platform for transparency and engagement with stakeholders.

Negative

• None.

CINCINNATI--(BUSINESS WIRE)-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2023 financial results after the market close on Monday, April 24, 2023. The Company will host a conference call the following morning, Tuesday, April 25, 2023, at 9:00 a.m. ET to discuss these results.

To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.

To access the conference call via webcast, visit the “Investors” section of Medpace’s website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,200 people across 40 countries as of December 31, 2022.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230328005763/en/

Investor Contact:

Lauren Morris

513.579.9911 x11994

l.morris@medpace.com

Media Contact:

Julie Hopkins

513.579.9911 x12627

j.hopkins@medpace.com

Source: Medpace Holdings, Inc.

FAQ

When will Medpace report its Q1 2023 financial results?

Medpace will report its Q1 2023 financial results after the market close on April 24, 2023.

What time is the Medpace conference call for Q1 2023 results?

The conference call for Medpace's Q1 2023 results is scheduled for April 25, 2023, at 9:00 a.m. ET.

How can I participate in the Medpace conference call?

To participate in the Medpace conference call, you must register in advance via the provided link.

Will there be a replay available for the Medpace conference call?

Yes, a replay of the Medpace conference call will be available approximately one hour after the call ends on their investor relations website.